~~<i id='D3F3F33A7F'><strike id='D3F3F33A7F'><tt id='D3F3F33A7F'><pre id='D3F3F33A7F'></pre></tt></strike></i>~~

Home» knowledge» comprehensive

comprehensive

author：knowledge 2025-09-29 07:44:23 Page View：1

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Some dementia cases could be undiagnosed liver disease
Next article： Continuity nursing helped my family in our darkest PICU moments

comprehensive

Tori Bowie and the unacceptable rates of Black maternal death

AlastairGrant/APThehorrorstoriesofBlackwomendyingorcomingclosetodeathinchildbirthneverseemtostopcomi

Medicare drug price negotiation’s day in court

AdobeYou’rereadingthewebeditionofD.C.Diagnosis,STAT’stwice-weeklynewsletteraboutthepoliticsandpolicy

Activists slam private health insurers over coverage restrictions

ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

What we need to know about Arena Bioworks

AdobeI’vespentagooddealofmycareerthinkingabouthowwestructureandfundresearchinthebiomedicalsciencesin

WSS

comprehensive

comprehensive

explore

comprehensive

What we need to know about Arena Bioworks